Back to Type 2 Diabetes

NCT03993379

NCT03993379
Terminated Phase 2 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You are 18 years of age or older
  • Your cancer can be measured on scans, as defined by a standard medical measurement system called RECIST v1.1 (confirm with trial site)
  • You are generally able to carry out daily activities with little or no limitation — rated 0 or 1 on a standard health scale used by doctors (confirm with trial site)
  • You are willing to provide tumor tissue and blood samples for research testing during the trial

Who may not be able to join:

  • You have received chemotherapy, radiation, immunotherapy, biological treatments, or any experimental treatment within the last 28 days before starting the trial
  • You have previously been treated with a type of therapy that uses specially modified immune cells called CAR-T cell therapy
  • You have a history of an active autoimmune disease — for example, inflammatory bowel disease, rheumatoid arthritis, lupus, or type 1 diabetes, among others (confirm with trial site for the full list)
  • You have ever had inflammation of the heart muscle (myocarditis), for any reason
  • You previously had to stop an immunotherapy treatment called a checkpoint inhibitor because of a serious side effect
  • You have a history of any condition that required you to take steroids at a dose of 10 mg or more of prednisone per day, or other medications that suppress the immune system
  • You have had a severe allergic or anaphylactic reaction to a type of drug called a monoclonal antibody, or are known to be allergic to the specific type of drug being tested in this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Terminated
Phase
Phase 2
Sponsor
CytomX Therapeutics
Registry
clinicaltrials_gov
Start date
20 November 2019
Est. completion
21 May 2020

Where this trial is recruiting

🇦🇺 Australia 🇳🇱 Netherlands 🇰🇷 South Korea 🇪🇸 Spain 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Overall Response Rate by RECIST v 1.1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov